Why the study?
Recurrences often occur after standard treatment for pulmonary embolism, necessitating extended anticoagulation, but traditional vitamin K antagonists require frequent monitoring and carry compliance and safety challenges.
Does rivaroxaban improve efficacy and safety in the treatment and long-term prevention of recurrent VTE in patients with pulmonary embolism compared to standard therapies?
Does rivaroxaban improve efficacy and safety in the treatment and long-term prevention of recurrent VTE in patients with pulmonary embolism compared to standard therapies?
Rivaroxaban is an effective and safe single-drug option for both acute treatment and long-term secondary prevention of pulmonary embolism.
Supports tailoring anticoagulation duration by PE provoking factor; leaves open optimal strategies pending randomized data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Koroleva et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: